FDA Brief

Warning letters Devices

FDA warning letter to

Unimicro Medical Systems-Shenzhen Co., Ltd.

High riskIssued Jan 6, 2022Posted Mar 22, 2022Center for Devices and Radiological Health

FDA warns Shenzhen maker of Veress needles that quality system violations make its devices adulterated and subject to U.S. import detention.

What happened

FDA inspected the Shenzhen facility from September 15 to 26, 2021. The investigator found missing or inadequate procedures and records for handling nonconforming product, design control, process validation, corrective actions, equipment calibration, and in-process testing, and also found no device history or master records. FDA said the company's October 8, 2021 corrective action plan was inadequate or not yet completed, and it deemed the Veress needles adulterated.

What FDA found

  1. The company had no adequate process to decide what to do with nonconforming product, and heat-sealed nonconforming packages were marked 'return to warehouse' without a final disposition, so their location and handling were unknown.

    21 CFR 820.90(a)
  2. The company could not provide documentation or evidence that design and development activities required by its own procedure were conducted for the Veress needles.

    21 CFR 820.30(a)
  3. The company lacked validation documentation and data for EtO sterilization, heat-sealing packaging, and UV glue curing, and staff were not familiar with process validation.

    21 CFR 820.75(b)
  4. The company did not define when a root cause analysis was needed or how severity was determined for corrective and preventive actions, and no root cause analysis was done for its two most recent CAPAs.

    21 CFR 820.100(a)
  5. The company could not provide calibration documentation for equipment used to manufacture U.S.-market Veress needles, including the leakage tester and push-and-pull tester.

    21 CFR 820.72(a)
  6. The company's in-process acceptance standard for Veress needles omitted connection bond testing and puncture testing, and quality staff were not familiar with those tests.

    21 CFR 820.80(c)

What FDA wants

FDA asks the company to respond in writing within 15 business days with specific corrections, supporting documentation, and a timetable for any longer actions. The company must correct the violations so the needles can be removed from detention without physical examination.

Who should pay attention

  • U.S. hospitals and surgical staff using Veress needles
  • distributors and importers of Unimicro devices
  • contract manufacturers or suppliers with U.S. device listings

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  3. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  4. BMC Medical Co., Ltd.

    BMC Medical’s G3X APAP devices were misbranded/adulterated after significant changes without a new 510(k) and an unreported firmware fix.

    High risk